Free Trial
NASDAQ:AYTU

Aytu BioPharma (AYTU) Stock Price, News & Analysis

Aytu BioPharma logo
$2.36 -0.15 (-5.98%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$2.36 0.00 (-0.21%)
As of 10/10/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aytu BioPharma Stock (NASDAQ:AYTU)

Advanced

Key Stats

Today's Range
$2.35
$2.59
50-Day Range
$1.71
$2.65
52-Week Range
$0.95
$2.82
Volume
185,780 shs
Average Volume
408,288 shs
Market Capitalization
$23.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.17
Consensus Rating
Moderate Buy

Company Overview

Aytu BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

AYTU MarketRank™: 

Aytu BioPharma scored higher than 73% of companies evaluated by MarketBeat, and ranked 263rd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aytu BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Aytu BioPharma has a consensus price target of $9.17, representing about 288.4% upside from its current price of $2.36.

  • Amount of Analyst Coverage

    Aytu BioPharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Aytu BioPharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aytu BioPharma is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aytu BioPharma is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aytu BioPharma has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Aytu BioPharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.55% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 0.58%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aytu BioPharma does not currently pay a dividend.

  • Dividend Growth

    Aytu BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.55% of the float of Aytu BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Aytu BioPharma has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aytu BioPharma has recently decreased by 0.58%, indicating that investor sentiment is improving.
  • News Sentiment

    Aytu BioPharma has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 1 article on an average week.
  • Search Interest

    13 people have searched for AYTU on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aytu BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.60% of the stock of Aytu BioPharma is held by insiders.

  • Percentage Held by Institutions

    Only 33.49% of the stock of Aytu BioPharma is held by institutions.

  • Read more about Aytu BioPharma's insider trading history.
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AYTU Stock News Headlines

Robinhood warning
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
See More Headlines

AYTU Stock Analysis - Frequently Asked Questions

Aytu BioPharma's stock was trading at $1.70 at the beginning of 2025. Since then, AYTU stock has increased by 38.8% and is now trading at $2.36.

Aytu BioPharma Inc. (NASDAQ:AYTU) issued its quarterly earnings data on Tuesday, September, 23rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.24. The firm had revenue of $15.14 million for the quarter, compared to analysts' expectations of $18.06 million. Aytu BioPharma had a positive trailing twelve-month return on equity of 13.77% and a negative net margin of 20.43%.
Read the conference call transcript
.

Shares of Aytu BioPharma reverse split on Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE).

Company Calendar

Last Earnings
9/23/2025
Today
10/10/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AYTU
CIK
1385818
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

High Price Target
$12.50
Low Price Target
$7.00
Potential Upside/Downside
+288.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.56 million
Net Margins
-20.43%
Pretax Margin
-20.71%
Return on Equity
13.77%
Return on Assets
3.28%

Debt

Debt-to-Equity Ratio
0.57
Current Ratio
1.26
Quick Ratio
1.07

Sales & Book Value

Annual Sales
$66.38 million
Price / Sales
0.35
Cash Flow
$0.35 per share
Price / Cash Flow
6.69
Book Value
$2.11 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
9,910,000
Free Float
9,555,000
Market Cap
$23.39 million
Optionable
Not Optionable
Beta
0.27

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:AYTU) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners